Myelodysplastic Syndromes: Iron Overload Consequences and Current Chelating Therapies

View More View Less
  • 1 From the Hematology Division, Stanford University Cancer Center, Stanford, California.

Chronic red blood cell transfusion support in patients with myelodysplastic syndromes (MDS) is often necessary but may cause hemosiderosis and its consequences. The pathophysiologic effects of iron overload relate to increased non-transferrin bound iron generating toxic oxygen free radicals. Studies in patients with MDS and thalassemia major have shown adverse clinical effects of chronic iron overload on cardiac function in patients who underwent polytransfusion. Iron chelation therapy in patients with thalassemia who were effectively chelated has prevented or partially reversed some of these consequences. A small group of patients with MDS who had undergone effective subcutaneous desferrioxamine (DFO) chelation for 1 to 4 years showed substantial hematologic improvements, including transfusion independence. However, because chronic lengthy subcutaneous infusions of DFO in elderly patients have logistic difficulties, this chelation therapy is generally instituted late in the clinical course. Two oral iron chelators, deferiprone (L1) and deferasirox (ICL670), provide potentially useful treatment for iron overload. This article reviews data indicating that both agents are relatively well tolerated, were at least as effective as DFO for decreasing iron burdens in comparative thalassemia trials, and (for deferiprone) were associated with improved cardiac outcomes. These outcomes could potentially alter the tissue siderosis-associated morbidity of patients with MDS, particularly those with pre-existing cardiac disease.

If the inline PDF is not rendering correctly, you can download the PDF file here.

Correspondence: Peter Greenberg, MD, Professor of Medicine, Stanford University Cancer Center, 875 Blake Wilbur Drive, Room 2335, Stanford, CA 94305-5821. E-mail: peterg@stanford.edu.
  • 1.

    Greenberg P. The myelodysplastic syndromes. In: Hoffman R, Benz E, Shattil S, et al., eds. Hematology: Basic Principles and Practice, 3rd ed. New York: Churchill Livingstone; 2000:11061129.

    • Search Google Scholar
    • Export Citation
  • 2.

    Cazzola M, Barosi G, Gobbi PG. Natural history of idiopathic refractory sideroblastic anemia. Blood 1988, 71:1124.

  • 3.

    Hellstrom-Lindberg E. Efficacy of erythropoietin in the myelodysplastic syndromes: a meta-analysis of 205 patients from 17 studies. Br J Haematol 1995;89:6771.

    • Search Google Scholar
    • Export Citation
  • 4.

    Schafer AI, Cheron RG, Dluhy R. Clinical consequences of acquired transfusional iron overload in adults. N Engl J Med 1981;304:319324.

  • 5.

    Jaeger M, Aul C, Sohngen D. Iron overload in polytransfused patients with MDS: the use of L1 for oral iron chelation. Drugs Today 1992;28[suppl A]:143147.

    • Search Google Scholar
    • Export Citation
  • 6.

    Greenberg P. Pathogenetic mechanisms underlying myelodysplastic syndrome. In: Greenberg PL, ed. Myelodysplastic Syndromes: Clinical and Biological Advances. Cambridge, UK: Cambridge University Press; 2005.

    • Search Google Scholar
    • Export Citation
  • 7.

    Farquhar MJ, Bowen DT. Oxidative stress and the myelodysplastic syndromes. Int J Hematol 2003;77:342350.

  • 8.

    Gotlib J, Greenberg P. Supportive care in myelodysplastic syndrome: hemopoietic cytokines and iron chelation therapy. In: Greenberg PL, ed. Myelodysplastic syndromes: clinical and biological advances. Cambridge, UK: Cambridge University Press; 2005.

    • Search Google Scholar
    • Export Citation
  • 9.

    Brittenham GM, Badman DG. Noninvasive measurement of iron: report of an NIDDK workshop. Blood 2003;101:1519.

  • 10.

    St Pierre TG, Clark PR, Chua-anusorn W. Noninvasive measurement and imaging of liver iron concentrations using proton magnetic resonance. Blood. 2005;105:855861.

    • Search Google Scholar
    • Export Citation
  • 11.

    Esposito BP, Breuer W, Sirankapracha P. Labile plasma iron in iron overload: redox activity and susceptibility to chelation. Blood 2003;102:26702677.

    • Search Google Scholar
    • Export Citation
  • 12.

    Cortelezzi A, Cattaneo C, Cristiani S. Non-transferrin-bound iron in myelodysplastic syndromes: a marker of ineffective erythropoiesis? Hematology 2000;1:153158.

    • Search Google Scholar
    • Export Citation
  • 13.

    Hershko C, Link G, Cabantchik ZI. Pathophysiology of iron overload. Ann NY Acad Sci 1998;850:191201.

  • 14.

    Deng X, Gao F, May WS Jr. Bcl2 retards G1/S cell cycle transition by regulating intracellular ROS. Blood 2003;102:31793185.

  • 15.

    Rajapaksa R, Ginzton N, Rott L, Greenberg PL: Altered oncogene expression and apoptosis in myelodysplastic syndrome marrow cells. Blood 1996;88:42754287.

    • Search Google Scholar
    • Export Citation
  • 16.

    Olivieri NF, Brittenham GM. Iron-chelating therapy and the treatment of thalassemia. Blood 1997;89:739761.

  • 17.

    Brittenham GM, Griffith PM, Nienhuis AW. Efficacy of deferoxamine in preventing complications of iron overload in patients with thalassemia major. N Engl J Med 1994;331:567573.

    • Search Google Scholar
    • Export Citation
  • 18.

    Angelucci E, Brittenham GM, McLaren CE. Hepatic iron concentration and total body iron stores in thalassemia major. N Engl J Med 2000;343:327331.

    • Search Google Scholar
    • Export Citation
  • 19.

    Davis B, O'Sullivan C, Porter J. The value of sequential monitoring of left ventricular ejection fraction in the management of thalassemia major. Blood 2004;104:263269.

    • Search Google Scholar
    • Export Citation
  • 20.

    Olivieri NF, Nathan DG, MacMillan JH. Survival in medically treated patients with homozygous beta-thalassemia. N Engl J Med 1994;331:574578.

    • Search Google Scholar
    • Export Citation
  • 21.

    Jensen PD, Heickendorff L, Pedersen B. The effect of iron chelation on haemopoiesis in MDS patients with transfusional iron overload. Br J Haematol 1996;94:288299.

    • Search Google Scholar
    • Export Citation
  • 22.

    Jensen PD, Jensen FT, Christensen T. Evaluation of myocardial iron by magnetic resonance imaging during iron chelation therapy with deferrioxamine: indication of close relation between myocardial iron content and chelatable iron pool. Blood 2003;101:46324639.

    • Search Google Scholar
    • Export Citation
  • 23.

    Pootrakul P, Sirankapracha P, Sankote J. Clinical trial of deferiprone iron chelation therapy in beta-thalassaemia/haemoglobin E patients in Thailand. Br J Haematol 2003;122:305310.

    • Search Google Scholar
    • Export Citation
  • 24.

    Greenberg P, Cox C, Le Beau MM. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997;89:20792088.

  • 25.

    Greenberg PL, Bennett J, Bloomfield C. NCCN Practice Guidelines for Myelodysplastic Syndromes, Version 2004. J Natl Compr Canc Netw 2003;1:456471.

    • Search Google Scholar
    • Export Citation
  • 26.

    Kersten MJ, Lange R, Smeets ME. Long-term treatment of transfusional iron overload with the oral iron chelator deferiprone (L1): a Dutch multicenter trial. Ann Hematol 1996;73:247252.

    • Search Google Scholar
    • Export Citation
  • 27.

    Olivieri NF, Brittenham GM, McLaren CE. Long-term safety and effectiveness of iron-chelation therapy with deferiprone for thalassemia major. N Engl J Med 1998;339:417423.

    • Search Google Scholar
    • Export Citation
  • 28.

    Stella M, Pinzello G, Maggio A. Iron chelation with oral deferiprone in patients with thalassemia. N Eng J Med 1998;339:17101711.

  • 29.

    Hoffbrand AV, Al-Refaie F, Davis B. Long-term trial of deferiprone in 51-transfusion-dependent iron overloaded patients. Blood 1998;91:295300.

    • Search Google Scholar
    • Export Citation
  • 30.

    Cohen AR, Galanello R, Piga A. Safety and effectiveness of long-term therapy with the oral iron chelator deferiprone. Blood 2003;102:15831587.

    • Search Google Scholar
    • Export Citation
  • 31.

    Ceci A, Baiardi P, Felisi M. The safety and effectiveness of deferiprone in a large-scale, 3-year study in Italian patients. Br J Haematol 2002;118:330336.

    • Search Google Scholar
    • Export Citation
  • 32.

    Hoffbrand AV, Cohen A, Hershko C. Role of deferiprone in chelation therapy for transfusional iron overload. Blood 2003;102:1724.

  • 33.

    Fischer R, Longo F, Nielsen P. Monitoring long-term efficacy of iron chelation therapy by deferiprone and desferrioxamine in patients with beta-thalassaemia major: application of SQUID biomagnetic liver susceptometry. Br J Haematol 2003;121:938948.

    • Search Google Scholar
    • Export Citation
  • 34.

    Addis A, Loebstein R, Koren G. Meta-analytic review of the clinical effectiveness of oral deferiprone (L1). Eur J Clin Pharmacol 1999;55:16.

    • Search Google Scholar
    • Export Citation
  • 35.

    Barman Balfour JA, Foster RH. Deferiprone: a review of its clinical potential in iron overload in beta-thalassaemia major and other transfusion-dependent diseases. Drugs 1999;58:553578.

    • Search Google Scholar
    • Export Citation
  • 36.

    Franchini M, Veneri D. Iron-chelation therapy: an update. Hematol J 2004;5:287292.

  • 37.

    Galanello R, Piga A, Alberti D. Safety, tolerability, and pharmacokinetics of ICL670, a new orally active iron-chelating agent in patients with transfusion-dependent iron overload due to beta-thalassemia. J Clin Pharmacol 2003;43:565572.

    • Search Google Scholar
    • Export Citation
  • 38.

    Piga A, Galanello R, Cappellini MD. Phase II study of ICL670, an oral chelator, in adult thalassaemia patients with transfusional iron overload: efficacy, safety, pharmacokinetics and pharmacodynamics after 18 months of therapy. Blood 2003;102[suppl 1]:121a.

    • Search Google Scholar
    • Export Citation
  • 39.

    Nisbet-Brown E, Olivieri NF, Giardina PJ. Effectiveness and safety of ICL670 in iron-loaded patients with thalassemia: a randomized, double blind, placebo-controlled, dose-escalation trial. Lancet 2003;361:15981602.

    • Search Google Scholar
    • Export Citation
  • 40.

    Gattermann N, Cazzola M, Greenberg P. The efficacy and tolerability of ICL670, a once-daily oral iron chelator, in patients with MDS and iron overload. Leuk Res 2005;29[suppl 1]:S67.

    • Search Google Scholar
    • Export Citation
  • 41.

    Gattermann N. Chelation therapy in myelodysplastic syndrome: update from recent clinical trials with oral agents. Leuk Res 2005;29[suppl 1]:S17.

    • Search Google Scholar
    • Export Citation
  • 42.

    Greenberg P, Dine G, Ganser A. Deferasirox (Exjade, ICL670) demonstrates dose-related effects on body iron levels related to transfusional iron intake in transfusion-dependent anemia. Blood 2005, in press.

    • Search Google Scholar
    • Export Citation
  • 43.

    Piga A, Gaglioti C, Fogliacco E. Comparative effects of deferiprone and deferoxamine on survival and cardiac disease in patients with thalassemia major: a retrospective analysis. Haematologica 2003;88:489496.

    • Search Google Scholar
    • Export Citation
All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 171 86 8
PDF Downloads 95 43 11
EPUB Downloads 0 0 0